<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Anixa Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/anixa-biosciences-inc</link>
<description>Latest news and press releases for Anixa Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 13:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/anixa-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835466278dffbe2df0e2f65.webp</url>
<title>Anixa Biosciences Inc</title>
<link>https://6ix.com/company/anixa-biosciences-inc</link>
</image>
<item>
<title>Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-issuance-of-mexican-patent-covering-breast-cancer-vaccine-technology</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-issuance-of-mexican-patent-covering-breast-cancer-vaccine-technology</guid>
<pubDate>Wed, 29 Apr 2026 13:10:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued Patent Number 432748, covering key aspects of the Company's breast cancer vaccine technology.</description>
</item>
<item>
<title>Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-presentation-of-its-ovarian-cancer-car-t-therapy-at-the-international-society-for-cell-and-gene-therapy-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-presentation-of-its-ovarian-cancer-car-t-therapy-at-the-international-society-for-cell-and-gene-therapy-2026-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 12:45:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.</description>
</item>
<item>
<title>Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-to-participate-in-redchips-biotech-resurgence-platforms-and-pipelines-of-todays-innovators-conference-on-april-16-2026</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-to-participate-in-redchips-biotech-resurgence-platforms-and-pipelines-of-todays-innovators-conference-on-april-16-2026</guid>
<pubDate>Thu, 09 Apr 2026 13:05:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today's Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.</description>
</item>
<item>
<title>Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-to-participate-in-water-tower-research-insights-conference-on-april-14-2026</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-to-participate-in-water-tower-research-insights-conference-on-april-14-2026</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trialOvarian cancer</description>
</item>
<item>
<title>Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-ceo-featured-on-smart-money-circle-interview-highlighting-advances-in-cancer-immunotherapy-programs</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-ceo-featured-on-smart-money-circle-interview-highlighting-advances-in-cancer-immunotherapy-programs</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the</description>
</item>
<item>
<title>Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-advances-breast-cancer-vaccine-toward-phase-2-after-positive-phase-1-results-cytovance-selected-for-cgmp-manufacturing-25</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-advances-breast-cancer-vaccine-toward-phase-2-after-positive-phase-1-results-cytovance-selected-for-cgmp-manufacturing-25</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of</description>
</item>
<item>
<title>Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-presentation-of-its-ovarian-cancer-car-t-therapy-clinical-trial-at-the-society-of-gynecologic-oncology-annual-meeting-on-womens-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-presentation-of-its-ovarian-cancer-car-t-therapy-clinical-trial-at-the-society-of-gynecologic-oncology-annual-meeting-on-womens-cancer</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial statusSAN JOSE, Calif., March 30, 2026</description>
</item>
<item>
<title>Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-featured-on-water-tower-research-healthcare-happenings-podcast</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-featured-on-water-tower-research-healthcare-happenings-podcast</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the</description>
</item>
<item>
<title>Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-receives-notice-of-allowance-from-korean-ministry-of-intellectual-property-moip-for-patent-covering-breast-cancer-vaccine-technology</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-receives-notice-of-allowance-from-korean-ministry-of-intellectual-property-moip-for-patent-covering-breast-cancer-vaccine-technology</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExpands global intellectual property coverage in markets with</description>
</item>
<item>
<title>Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-to-host-2026-annual-meeting-of-stockholders-and-provide-corporate-update-highlighting-recent-clinical-and-regulatory-progress</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-to-host-2026-annual-meeting-of-stockholders-and-provide-corporate-update-highlighting-recent-clinical-and-regulatory-progress</guid>
<pubDate>Mon, 02 Mar 2026 14:10:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders.</description>
</item>
<item>
<title>Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-dr-jose-conejo-garcia-will-keynote-the-south-carolina-clinical-and-translational-research-institute-2026-retreat</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-dr-jose-conejo-garcia-will-keynote-the-south-carolina-clinical-and-translational-research-institute-2026-retreat</guid>
<pubDate>Mon, 23 Feb 2026 13:55:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine and the co-inventor of Anixa's CAR-T technology, will be a keynote speaker at the South Carolina Clinical & Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Dis</description>
</item>
<item>
<title>Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-reports-encouraging-patient-130000148</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-reports-encouraging-patient-130000148</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol amendment that enables substantial dose escalation.</description>
</item>
<item>
<title>Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-secures-united-states-140000536</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-secures-united-states-140000536</guid>
<pubDate>Mon, 02 Feb 2026 14:00:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names (USAN) Council approved "liraltagene autoleucel" for the non-proprietary name of the Company's novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. This U.S. approval follows the earlier approval for international use of the name by the International Nonproprietary Names (INN) Expert Committee</description>
</item>
<item>
<title>Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-receives-notice-allowance-133000309</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-receives-notice-allowance-133000309</guid>
<pubDate>Tue, 27 Jan 2026 13:30:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in Mexic</description>
</item>
<item>
<title>Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-transfer-ind-134500820</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-transfer-ind-134500820</guid>
<pubDate>Mon, 15 Dec 2025 13:45:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed the transfer of the Investigational New Drug application ("IND") for its breast cancer vaccine from Cleveland Clinic. Anixa is now the trial sponsor for future development of its breast cancer vaccine. The transfer of the IND is a natural and planned step in the progresson of the vaccine's development.</description>
</item>
<item>
<title>Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-positive-phase-230200863</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-positive-phase-230200863</guid>
<pubDate>Thu, 11 Dec 2025 23:02:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the presentation of final data from the Phase 1 clinical trial of its investigational breast cancer vaccine (NCT04674306) at the 2025 San Antonio Breast Cancer Symposium (SABCS). The trial was conducted in collaboration with Cleveland Clinic and funded by a grant from the U.S. Department of Defense.</description>
</item>
<item>
<title>Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-participate-water-tower-140000758</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-participate-water-tower-140000758</guid>
<pubDate>Wed, 10 Dec 2025 14:00:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Monday, December 15, 2025, at 1:00pm ET.</description>
</item>
<item>
<title>Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-world-health-131500148</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-announces-world-health-131500148</guid>
<pubDate>Mon, 17 Nov 2025 13:15:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) approved "liraltagene autoleucel" for the non-proprietary name of the Company's novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The INN nomenclature scheme for CAR-T cell therapies follows a two-word structure describing</description>
</item>
<item>
<title>Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-awarded-key-u-140000572</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-awarded-key-u-140000572</guid>
<pubDate>Wed, 12 Nov 2025 14:00:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,472,205 on November 18, 2025, covering key aspects of the Company's breast cancer vaccine technology. The patent protects novel methods of inducing an immune response to α-lactalbumin protein—a protein typically found only in normal breast tissue dur</description>
</item>
<item>
<title>Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025</title>
<link>https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-participate-water-tower-153000494</link>
<guid isPermaLink="true">https://6ix.com/company/anixa-biosciences-inc/news/anixa-biosciences-participate-water-tower-153000494</guid>
<pubDate>Mon, 10 Nov 2025 15:30:00 GMT</pubDate>
<description>Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Tuesday, November 11, 2025, at 11:00am PT.</description>
</item>
</channel>
</rss>